美国弗雷德哈钦森癌症研究中心Leonidas Stamatatos、Andrew T. McGuire、Marie Pancera等研究人员，合作研发出针对新冠病毒（SARS-CoV-2）不同表位的有效中和抗体。这一研究成果于2020年6月5日发表在《免疫》上。

Title: Analysis of a SARS-CoV-2 infected individual reveals development of potent neutralizing antibodies to distinct epitopes with limited somatic mutation

Author: Emilie Seydoux, Leah J. Homad, Anna J. MacCamy, K. Rachael Parks, Nicholas K. Hurlburt, Madeleine F. Jennewein, Nicholas R. Akins, Andrew B. Stuart, Yu-Hsin Wan, Junli Feng, Rachael E. Whaley, Suruchi Singh, Michael Boeckh, Kristen W. Cohen, M. Juliana McElrath, Janet A. Englund, Helen Y. Chu, Marie Pancera, Andrew T. McGuire, Leonidas Stamatatos

Issue&Volume: 2020-06-05

Abstract: Antibody responses develop following SARS-CoV-2 infection, but little is known about their epitope specificities, clonality, binding affinities, epitopes and neutralizing activity. We isolated B cells specific for the SARS-CoV-2 envelope glycoprotein spike (S) from a COVID-19-infected subject twenty-one days after the onset of clinical disease. Forty-five S-specific monoclonal antibodies were generated. They had undergone minimal somatic mutation, with limited clonal expansion and three bound the receptor binding domain (RBD). Two antibodies neutralized SARS-CoV-2. The most potent antibody bound the RBD and prevented binding to the ACE2 receptor, while the other bound outside the RBD. Thus, most anti-S antibodies that were generated in this patient during the first weeks of COVID-19 infection were non-neutralizing and target epitopes outside the RBD. Antibodies that disrupt the SARS-CoV-2 S-ACE2 interaction can potently neutralize the virus without undergoing extensive maturation. Such antibodies have potential preventive and/or therapeutic potential and can serve as templates for vaccine-design.

DOI: 10.1016/j.immuni.2020.06.001

Source: https://www.cell.com/immunity/fulltext/S1074-7613(20)30231-4